Opendata, web and dolomites

iConsensus SIGNED

Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "iConsensus" data sheet

The following table provides information about the project.

Coordinator
KUNGLIGA TEKNISKA HOEGSKOLAN 

Organization address
address: BRINELLVAGEN 8
city: STOCKHOLM
postcode: 100 44
website: www.kth.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.iconsensus.eu
 Total cost 9˙400˙000 €
 EC max contribution 4˙700˙000 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-10-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KUNGLIGA TEKNISKA HOEGSKOLAN SE (STOCKHOLM) coordinator 1˙387˙000.00
2    MICRONIT MICROTECHNOLOGIES BV NL (ENSCHEDE) participant 650˙000.00
3    PRESENS PRECISION SENSING GMBH DE (Regensburg) participant 454˙000.00
4    RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN DE (AACHEN) participant 374˙000.00
5    UNIVERSITAET HOHENHEIM DE (STUTTGART) participant 355˙500.00
6    KANTISTO BV NL (BAARN) participant 308˙500.00
7    M2P-LABS GMBH DE (BAESWEILER) participant 300˙000.00
8    UNIVERSITE DE MONS BE (MONS) participant 300˙000.00
9    PAIA BIOTECH GMBH DE (KOLN) participant 250˙000.00
10    IPRATECH SA BE (MONS) participant 150˙000.00
11    SVANHOLM.COM APS DK (VORDINGBORG) participant 100˙000.00
12    IPRASENSE FR (CLAPIERS) participant 71˙000.00
13    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
14    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
15    PFIZER LIMITED UK (SANDWICH) participant 0.00
16    RENTSCHLER BIOPHARMA SE DE (LAUPHEIM) participant 0.00
17    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00
18    SYNTHON BIOPHARMACEUTICALS BV NL (NIJMEGEN) participant 0.00
19    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

iConsensus will provide innovative analytical, hardware, software and high-throughput (HTP) solutions for the development, monitoring and control of mammalian cell cultivation process producing biopharmaceuticals. iConsensus will develop an analytical platform with on-line/at-line sensors and detection methods measuring multiple factors in the cell culture and the produced biopharmaceutical. Under advanced data management, the analytical platform will be integrated in new micro-bioreactors for HTP screening on one hand and in classical stirred tank vessel bioreactor on the other hand. Based on the analytical information, feedback control will be applied. When deemed suitable, implementation in GMP production of the sensing and control tools will be carried on.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ICONSENSUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ICONSENSUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

TRIC-TB (2019)

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Read More  

FAIRplus (2019)

FAIRplus

Read More